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Abstract 19 
Vaccinia virus (VACV) strain MVA is a highly attenuated vector for vaccines that is being explored in 20 
clinical trials. We compared the CD8+ T cell immunogenicity of MVA with that of a virulent laboratory 21 
strain of VACV (strain WR) in BALB/c mice by examining epitope-specific responses as well as 22 
estimating the total number of activated CD8+ T cells, irrespective of specificity. We found that MVA 23 
elicited total CD8+ T cell responses that were reduced by at least 20-fold compared with strain WR in 24 
BALB/c mice. In C57Bl/6 mice we also found a substantial difference in immunogenicity between 25 
these VACV strains, but it was more modest at around 5-fold. Of note, the size of responses to the 26 
virulent WR virus were similar in both strains of mice suggesting that BALB/c mice can mount robust 27 
CD8+ T cell responses to VACV. While the data for total responses clearly showed that MVA overall is 28 
poorly immunogenic in BALB/c mice, we found one epitope for which strong responses were made 29 
irrespective of virus strain. Therefore in the context of a vaccine, some recombinant epitopes may have 30 
similar immunogenicity when expressed from MVA and other strains of VACV, but we would expect 31 
these to be exceptions. These data show clearly the substantial difference in immunogenicity between 32 
MVA and virulent VACV strains and suggest that the impact of host genetics on responses to 33 
attenuated vaccine vectors like MVA requires more consideration. 34 
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Introduction 43 
Since its use to eradicate smallpox, vaccinia virus (VACV) has attracted considerable interest as a 44 
recombinant vaccine vector, having a large capacity for foreign genes and inherent immunogenicity.1, 2 45 
As a result, vaccines based on highly attenuated strains of VACV, such as Modified Vaccinia Ankara 46 
(MVA), have entered clinical trials.3, 4 Mouse models are invaluable for developing vaccines, but are 47 
frequently limited to a single inbred strain of mice. Further, it is assumed that data from virulent VACV 48 
strains such as Western Reserve (WR) can be directly extrapolated to attenuated vectors, even though  49 
virulence and antigen dose are linked to immunogenicity. In this context, the CD8+ T cell (TCD8+) 50 
response to VACV has been most extensively investigated using C57Bl/6 mice and for VACV strain 51 
WR.5, 6 Here we ask whether this data can be reasonably generalized to other strains of VACV, 52 
including MVA and to BALB/c mice, a commonly used inbred strain preferred for some infectious 53 
models.7, 8  54 
 55 
Results and Discussion 56 
First, we measured TCD8+ responses in BALB/c mice 7 days after immunization with VACV strains 57 
MVA, Copenhagen and WR using peptides published as H-2d-presented epitopes 9, 10 to restimulate 58 
splenocytes prior to intracellular staining for IFN-γ (IFN-γ ICS).11 This set of native VACV epitopes 59 
was used rather than a single native (or recombinant) epitope to obtain representative results and 60 
because previous studies have shown that changes in immunodominance can be misinterpreted as 61 
differences in immunogenicity.12 Immunization with WR resulted in larger TCD8+ responses than with 62 
Copenhagen and especially MVA for almost all peptides (Fig. 1A). The only exception was E3140, 63 
which elicits a similar sized TCD8+ response for all strains of VACV. Comparisons between the virus 64 
strains were similar in mice >30 days after immunization (not shown). 65 
 66 
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Lack of conservation of key epitopes across the VACV strains complicates the experiment above. In 67 
particular, the most immunogenic epitope in WR (F226(Y); SPYAAGYDL) exists as a variant (F226(G); 68 
SPGAAGYDL) in Copenhagen and MVA and in these viruses anti-F226 responses are far less 69 
prominent. A5275 and B249 are absent in MVA and  exists as two alternate variants (GFIRSLQTI in 70 
WR and SFIRSLQNI in Copenhagen and MVA). Both versions of this peptide were used in all IFN-γ 71 
ICS assays, but for all the virus strains produced the same result and for simplicity we show data from 72 
homologous variants for each virus. 73 
  74 
As noted above, the F226(G) variant of the immunodominant F226(Y) epitope in WR elicits relatively 75 
weak TCD8+responses from Copenhagen and even more so from MVA, but it is not clear to what extent 76 
this is due to the epitope variant or the virus strain background. To distinguish between these 77 
possibilities and to allow matching of a known immunodominant epitope between WR and MVA, we 78 
made recombinants of both, engineered such that they expressed the alternate variant of the F226 79 
epitope. WR F2G had the usual dominant WR F226(Y) epitope replaced with F226(G) and MVA F2Y had 80 
the reverse replacement. After immunizing mice with these viruses, we found that replacement of the 81 
F226(Y) epitope of WR with F226(G) in WR F2G substantially reduced F226-specific responses, but other 82 
specificities were not altered (Fig. 1B). Conversely, the introduction of F226(Y) to MVA, while 83 
improving F226–specific TCD8+ responses compared with MVA, produced a response that was less than 84 
a quarter of that elicited by WR. Indeed WR F2G, induced a significantly higher F226-specific response 85 
than MVA F2Y, even though they expressed subdominant and immunodominant variants, respectively 86 
(p=0.0256). Summing up the responses to the conserved epitopes tested in this experiment (including 87 
only the appropriate variant of F226) showed that MVA F2Y was much less immunogenic than WR 88 
even though it shared the immunodominant F226(Y) (Fig. 1C). Likewise, WR F2G remained 89 
substantially more immunogenic than MVA, despite both viruses containing the subdominant F226(G) 90 
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epitope. These data suggest that MVA is inherently poorly immunogenic in BALB/c mice compared 91 
with WR. 92 
 93 
To ensure that the results above were not unwittingly biased by the set of epitopes that we had 94 
available, we used an epitope-independent method of measuring TCD8+ responses. Upon activation of 95 
TCD8+ during VACV immunization in vivo, CD62L and granzyme B (GzmB) are down- and up-96 
regulated respectively. Therefore the expression of intracellular GzmB and surface CD62L on 97 
uncultured TCD8+ can be used as a surrogate measure of the total acute anti-VACV response in the acute 98 
phase.13 Using this method demonstrated that while WR induced a large response of around 60% of 99 
TCD8+ in BALB/c, Copenhagen was less immunogenic and MVA elicited responses around 8-fold lower 100 
(Figure 2A-B left). When the data were analyzed as the total number of activated TCD8+ cells per 101 
spleen, the difference between WR and MVA was even more striking at >30-fold (Figure 2B right). We 102 
were concerned that this method might be missing TCD8+ primed by MVA if GzmB expression or 103 
CD62L down regulation were not as marked on these cells such that they fell outside the gate, which 104 
was set on the basis of samples from WR-infected mice. To address this we used MVA F2Y that had 105 
poor immunogenicity like MVA but allowed the use of F226(Y)-loaded DimerX (similar to peptide-106 
MHC-tetramer) reagents to identify a population of virus-specific TCD8+ that could be compared with 107 
similar cells from WR-infected mice (Figure 2C). After MVA F2Y and WR immunization, 61.4% and 108 
93.5% of F226(Y)-specific TCD8+ were able to be identified as activated according to their CD62L and 109 
GzmB profile, respectively (Figure 2C). This suggests our method underestimates numbers of TCD8+ 110 
primed by both viruses in BALB/c mice, but more so for MVA than WR. Taking these different levels 111 
of underestimation into account, the difference in total response elicited by these viruses was ~20-fold. 112 
 113 
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Less virulent strains of VACV have been found previously to induce lower responses in C57Bl/6 mice, 114 
but MVA was not tested and the differences were not as large as we show here in BALB/c mice.14 To 115 
examine this, we used CD62L and GzmB to compare responses to immunization with VACV strains in 116 
C57Bl/6 mice (Figure 2D). Around 60% of TCD8+ responded to WR in these mice, similar to WR in 117 
BALB/c mice and a previous study.13 Copenhagen and MVA were less immunogenic than WR, but the 118 
difference was not as great as was seen for BALB/c mice. In C57Bl/6 mice, MVA induced responses 119 
that were 2.5-fold lower than WR when analyzed as a percent of TCD8+ and 5-fold when total numbers 120 
of activated cells in the spleen were compared. 121 
 122 
These data show that BALB/c and C57Bl/6 mice mount similar sized TCD8+ responses to WR, so the 123 
former are not necessarily compromised in their ability to respond to VACV in general. However, we 124 
did note that BALB/c mice made poorer responses to strain Copenhagen than did C57Bl/6 mice 125 
(around 2-fold less). It is possible that BALB/c mice need relatively higher levels of infection to 126 
generate the same TCD8+ response compared with C57Bl/6 mice and the high virulence of WR masks 127 
this defect. Understanding differences in immune responses to virulent viruses across mouse strains is 128 
complicated because it is not possible to dissect the roles of virus burden, antigen loads and 129 
inflammation, all of which will vary with virus replication and spread. However for a non-replicating 130 
virus such as MVA, which causes no pathology and has limited spread15-17, these complications are not 131 
a problem. Therefore the simplest explanation of these data is that BALB/c mice have a simple defect 132 
in priming TCD8+ responses to MVA compared with C57Bl/6 mice. To determine if the difference in 133 
anti-MVA TCD8+ numbers in the two mouse strains could be resolved at a higher dose, we compared 134 
responses in mice immunized with the standard 1×106 PFU with a 10-fold higher dose (Figure 2E). The 135 
number, but not percent of TCD8+ was significantly increased in BALB/c mice given 1×107 PFU but the 136 
response remained around a third of that elicited by the standard dose in C57Bl/6 mice. In C57Bl/6 137 
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mice, no significant increase in response was seen for the higher dose, supporting the notion that TCD8+ 138 
responses in BALB/c mice might be more dependent on high doses of VACV antigen. They also 139 
underscore the defect of BALB/c mice in making TCD8+ responses to MVA. 140 
 141 
When examining individual epitopes, the poor immunogenicity we describe here was not apparent for 142 
one epitope. Responses to E3140 were comparable in all the strains of VACV tested and this suggests 143 
that for at least one epitope, MVA can prime good TCD8+ responses. This most likely explains the 144 
apparent superiority of a recombinant MVA over a thymidine kinase negative WR in priming TCD8+ to 145 
an encoded β-galactosidase epitope when the opposite result was found for VACV-specific responses.16 146 
The interpretation in that case was that the induction of modest anti-vector and good anti-recombinant 147 
antigen responses is a desirable general characteristic of recombinant MVA vaccines16. However in the 148 
light of the data here, perhaps the previous result reflects a fortuitous choice of foreign antigen rather 149 
than a general principle. Looking across the native epitopes we tested (e.g. Figure 1B), it is clear that 150 
E3140 is an exception rather than the rule and there is no reason to expect that recombinant antigens in 151 
vaccine would follow a different pattern. 152 
 153 
In summary, MVA elicits many fewer TCD8+ than WR in BALB/c and C57Bl/6 mice, but this was 154 
especially notable in BALB/c. The contrast between these mouse strains highlights the importance of 155 
host genetic background in responses to attenuated vaccine vectors such as MVA. 156 
 157 
Methods 158 
Viruses 159 
The unmodified VACV used were low passage stocks grown in BHK-21. WR refers to WR (NIH TC-160 
adapted), ATCC VR-1354, sequence accession AY243312.1. MVA refers to ‘clone 1’ characterized 161 
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extensively in17 that was derived at NIH from an original isolate harvested after 572 passages in 162 
primary chick cells in 1974. Both were provided by Bernard Moss (NIH). 163 
 164 
Mice and infections 165 
Female C57Bl/6 and BALB/c mice greater than 8 weeks of age were housed and experiments were 166 
done according to ethical requirements and under an approval from the Australian National University 167 
Animal Ethics and Experimentation Committee. Mice were injected via the intraperitoneal (i.p.) route 168 
with 1×106 PFU of virus in 200 μl PBS except in Figure 2E where some mice received 1×107 PFU. 169 
 170 
TCD8+ assays 171 
Mice were euthanized 7 days after infection and single cell suspensions of spleens used in the 172 
following assays12: A) Splenocytes were cultured with synthetic peptides at 0.1 μM in the presence of 173 
brefeldin A for 4 hours before surface staining for CD8 (clone 53-6.7; BioLegend), fixation with 1% 174 
paraformaldehyde and intracellular staining for IFN-γ (clone XMG1.2; BioLegend).   Peptide 175 
sequences used were: F226(Y), SPYAAGYDL; F226(G),SPGAAGYDL; A5275, KYGRLFNEI; E3140, 176 
VGPSNSPTF; C674(G), GFIRSLQTI; C674(S), SFIRSLQTI; I890, LPNPAFIHI; I8511, QYIYSEHTI; 177 
A3190, IYSPSNHHI; B249, KYMWCYSQV; D1797, KYEGPFTTT; (Mimotopes or Genscript).9, 10 The 178 
use of this method to make quantitative comparisons of  TCD8+ responses after VACV infection has 179 
been validated rigorously11. B) splenocytes were stained for surface CD8 (clone 53-6.7) and CD62L 180 
(clone 53-6.7, BioLegend) before fixing and staining for intracellular GzmB (clone GB12; Invitrogen, 181 
supplied by Caltag).13 C) Splenocytes were stained for CD8 (clone 53-6.7) and with F226(Y)-loaded H-182 
2Ld:Ig fusion protein (DimerX; BD Biosciences) pre-bound with α-mouse IgG1-PE (clone A85-1, BD 183 
Biosciences).18 In some instances surface CD62L and intracellular GzmB were also assessed as above 184 
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and as published.13 For all assays data were acquired using an LSR II flow cytometer (BD Biosciences) 185 
and analysis was done with the aid of with Flowjo software (Treestar). 186 
 187 
Generation of VACVs with the alternate F226 peptide 188 
Recombinant VACV WR expressing the alternate F226 peptide SPGAAGYDL and recombinant VACV 189 
MVA expressing the alternate F226 SPYAAGYDL peptide were engineered using a transient dominant 190 
method in which unstable intermediates were enriched and identified through the use of a fusion 191 
protein between enhanced green fluorescent protein (GFP) and BsdR (confers resistance to blasticidin). 192 
19  The sequences used to encode the F226 epitope were altered to include identifying restriction enzyme 193 
sites and some additional changes to allow each recombinant to be distinguished from its parent by 194 
PCR, but the only amino acid changes were the desired glycine and tyrosine substitutions. 195 
 196 
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Figure legends 204 
Figure 1. Peptide-specific TCD8+ responses to different strains of VACV in BLAB/c mice and impact 205 
of sequence variation in the immunodominant F226 peptide. Groups of BALB/c mice were 206 
immunized with 1×106 PFU of VACV i.p. and 7d later peptide-specific TCD8+ cell responses were 207 
measured using IFN-γ ICS. (A) Average percentages (and SEMs) of TCD8+ cells from BALB/c mice 208 
infected with VACV WR, Copenhagen (Cop) or MVA that produce IFN-γ in ex vivo stimulations with 209 
the indicated peptides.  (B) Average percentages (and SEMs) of TCD8+ cells from BALB/c mice 210 
infected with VACV WR, WR F2G, MVA or MVA F2Y that produce IFN-γ in ex vivo stimulations 211 
with the indicated peptides. (C) Sum of TCD8+ cell responses to the 7 epitopes conserved across all 212 
strains shown in B (including only the appropriate F226 variant). Data are means and SEM from two 213 
independent experiments, each with n = 5 - 10 (*p < 0.01, Mann Whitney test). 214 
 215 
Figure 2. Total TCD8+ cell response to VACV strains in BALB/c and C57Bl/6 mice. Groups mice were 216 
immunized i.p. with 1×106 or 1×107 PFU of VACV strains as shown or were control (naïve) injected 217 
with 200 µl PBS, i.p.. After 7 days splenocytes were analyzed for surface CD62L and intracellular 218 
GzmB (A, B, D and E) or F226(Y)-loaded DimerX-binding, CD62L and GzmB (C). (A) Representative 219 
flow cytometry plots (gated on CD8+ events) for each VACV strain and naïve control in BALB/c mice. 220 
(B) Averages (and SEM) of CD62Llo GzmBhi events  in BALB/c mice analyzed as a % of CD8+ events 221 
(left) and total numbers of CD8+, CD62Llo GzmBhi events (right). Data are from 2 for uninfected mice, 222 
6 Copenhagen-, 6 MVA- and 12 WR-infected mice across two experiments. (C) Representative flow 223 
cytometry plots gated on CD8+ (top row), and on F226(Y)-DimerX+, as shown on top plots (bottom row) 224 
of splenocytes from mice immunized with MVA F2Y or WR in BALB/c mice. Graph on right shows 225 
average percent (and SEM) of  CD62LloGzmBhi amongst F226(Y)-specific TCD8+. (D) Same as B, but 226 
using C57Bl/6 mice. (E) Comparison of two doses of MVA (1×106 and 1×107 PFU in BALB/c and 227 
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C57Bl/6 mice as shown on graphs. Total numbers of activated TCD8+ per spleen are on the left and the 228 
percent of activated cells amongst CD8+ events on the right. (D and E) Data are from 2 uninfected mice 229 
and 6 mice infected with each VACV strains across two experiments. (*p < 0.05, Mann Whitney test).230 
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